5-乙氧基-2-吡啶乙酸 | 683233-70-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-乙氧基-2-吡啶乙酸
• 中文别名: 2-(5-乙氧基吡啶-2-基)乙酸
• 英文名称: 5-ethoxy-2-pyridylacetic acid
• 英文别名: 2-(5-Ethoxypyridin-2-yl)acetic acid
• CAS: 683233-70-7
• 化学式: C₉H₁₁NO₃
• mdl: MFCD18261530
• 分子量: 181.191
• InChiKey: JTAORGBESRGYTR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-乙氧基-2-吡啶乙酸 、 3-amino-4-[(Cyclopropylmethyl)amino]benzonitrile 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成
  参考文献：
  名称：

  Novel benzimidazole derivatives as selective CB2 agonists

  摘要：

  The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (> 1000-fold) over the CB1 receptor. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.05.073

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2004035548A1

  公开（公告）日：2004-04-29

  Compounds of formula (I) wherein RF1, RF2, Z, R1, R2, Ar, X and Y are as defined in the specification as well as salts and pharmaceutical compositions including the compounds were prepared. These compounds are useful in therapy, in particular in the management of pain.

  式（I）中的化合物，其中RF1，RF2，Z，R1，R2，Ar，X和Y的定义如规范中所述，以及包括这些化合物的盐和药物组合物已经制备。这些化合物在治疗中很有用，特别是在疼痛管理中。
• Novel Compounds
  申请人：Page Daniel

  公开号：US20070105893A1

  公开（公告）日：2007-05-10

  Compounds of formula (I) wherein R F1 , R F2 , Z, R 1 , R 2 , Ar, X and Y are as dcfined in thc specification as wcll as salts and pharmaceutical compositions including the compounds were prepared. These compounds are useful in therapy, in particular in the management of pain.

  化合物的公式（I），其中RF1，RF2，Z，R1，R2，Ar，X和Y的定义如规范所述，以及包括这些化合物的盐和制药组合物已经制备。这些化合物在治疗中是有用的，特别是在疼痛管理方面。
• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1554254A1

  公开（公告）日：2005-07-20
• US7407968B2
  申请人：——

  公开号：US7407968B2

  公开（公告）日：2008-08-05
• Novel benzimidazole derivatives as selective CB2 agonists
  作者：Daniel Pagé、Elise Balaux、Luc Boisvert、Ziping Liu、Claire Milburn、Maxime Tremblay、Zhongyong Wei、Simon Woo、Xuehong Luo、Yun-Xing Cheng、Hua Yang、Sanjay Srivastava、Fei Zhou、William Brown、Miroslaw Tomaszewski、Christopher Walpole、Leila Hodzic、Stéphane St-Onge、Claude Godbout、Dominic Salois、Keymal Payza

  DOI：10.1016/j.bmcl.2008.05.073

  日期：2008.7

  The preparation and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety are reported. They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies. They also demonstrated good to excellent selectivity (> 1000-fold) over the CB1 receptor. (C) 2008 Elsevier Ltd. All rights reserved.